A clinical-stage biotechnology company in immunotherapy

Focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmmune diseases.

Our latest press release

17/01/2022

Download

T-cell activation through neo-epitopes
Transforming tumor microenvironment
suppressive cells into effector cells

Down regulating T effector cells to decrease immunological reactivity

Up regulating regulatory
T-cells to develop immune tolerance

Therapeutic vaccine
Prophylactic vaccine

Based on T-cells

T-cell activation through neo-epitopes
Transforming tumor microenvironment
suppressive cells into effector cells

Down regulating T effector cells to decrease immunological reactivity

Up regulating regulatory
T-cells to develop immune tolerance

Therapeutic vaccine
Prophylactic vaccine

Based on T-cells

Premier international pharma, clinical and academic collaborations to speed up the delivery of our product candidates to patients in need

To download the documents